The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase

Astrid Kaiser, Kayoko Nishi, Fredric A Gorin, Donal A. Walsh, E. Morton Bradbury, Joachim B. Schnier

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Flavopiridol has been shown to induce cell cycle arrest and apoptosis in various tumor cells in vitro and in vivo. Using immobilized flavopiridol, we identified glycogen phosphorylases (GP) from liver and brain as flavopiridol binding proteins from HeLa cell extract. Purified rabbit muscle GP also bound to the flavopiridol affinity column. GP is the rate-limiting enzyme in intracellular glycogen breakdown. Flavopiridol significantly inhibited the AMP-activated GP-b form of the purified rabbit muscle isoenzyme (IC 50 of 1 μM at 0.8 mM AMP), but was less inhibitory to the active phosphorylated form of GP, GP-a (IC 50 of 2.5 μM). The AMP-bound GP-a form was poorly inhibited by flavopiridol (40% at 10 μM). Increasing concentrations of the allosteric effector AMP resulted in a linear decrease in the GP-inhibitory activity of flavopiridol suggesting interference between flavopiridol and AMP. In contrast the GP inhibitor caffeine had no effect on the relative GP inhibition by flavopiridol, suggesting an additive effect of caffeine. Flavopiridol also inhibited the phosphorylase kinase-catalyzed phosphorylation of GP-b by inhibiting the kinase in vitro. Flavopiridol thus is able to interfere with both activating modifications of GP-b, AMP activation and phosphorylation. In A549 NSCLC cells flavopiridol treatment caused glycogen accumulation despite of an increase in GP activity, suggesting direct GP inhibition in vivo rather than inhibition of GP activation by phosphorylase kinase. These results suggest that the cyclin-dependent kinase inhibitor flavopiridol interferes with glycogen degradation, which may be responsible for flavopiridol's cytotoxicity and explain its resistance in some cell lines.

Original languageEnglish (US)
Pages (from-to)179-187
Number of pages9
JournalArchives of Biochemistry and Biophysics
Volume386
Issue number2
DOIs
StatePublished - Feb 15 2001

Fingerprint

alvocidib
Glycogen Phosphorylase
Cyclin-Dependent Kinases
Adenosine Monophosphate
Phosphorylase b
Phosphorylase Kinase
Glycogen
Phosphorylation
Cells
Caffeine
Muscle

Keywords

  • A549
  • Cancer
  • Flavopiridol
  • Glycogen phosphorylase

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. / Kaiser, Astrid; Nishi, Kayoko; Gorin, Fredric A; Walsh, Donal A.; Morton Bradbury, E.; Schnier, Joachim B.

In: Archives of Biochemistry and Biophysics, Vol. 386, No. 2, 15.02.2001, p. 179-187.

Research output: Contribution to journalArticle

Kaiser, Astrid ; Nishi, Kayoko ; Gorin, Fredric A ; Walsh, Donal A. ; Morton Bradbury, E. ; Schnier, Joachim B. / The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. In: Archives of Biochemistry and Biophysics. 2001 ; Vol. 386, No. 2. pp. 179-187.
@article{064223b842504c129337da65a3d0e861,
title = "The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase",
abstract = "Flavopiridol has been shown to induce cell cycle arrest and apoptosis in various tumor cells in vitro and in vivo. Using immobilized flavopiridol, we identified glycogen phosphorylases (GP) from liver and brain as flavopiridol binding proteins from HeLa cell extract. Purified rabbit muscle GP also bound to the flavopiridol affinity column. GP is the rate-limiting enzyme in intracellular glycogen breakdown. Flavopiridol significantly inhibited the AMP-activated GP-b form of the purified rabbit muscle isoenzyme (IC 50 of 1 μM at 0.8 mM AMP), but was less inhibitory to the active phosphorylated form of GP, GP-a (IC 50 of 2.5 μM). The AMP-bound GP-a form was poorly inhibited by flavopiridol (40{\%} at 10 μM). Increasing concentrations of the allosteric effector AMP resulted in a linear decrease in the GP-inhibitory activity of flavopiridol suggesting interference between flavopiridol and AMP. In contrast the GP inhibitor caffeine had no effect on the relative GP inhibition by flavopiridol, suggesting an additive effect of caffeine. Flavopiridol also inhibited the phosphorylase kinase-catalyzed phosphorylation of GP-b by inhibiting the kinase in vitro. Flavopiridol thus is able to interfere with both activating modifications of GP-b, AMP activation and phosphorylation. In A549 NSCLC cells flavopiridol treatment caused glycogen accumulation despite of an increase in GP activity, suggesting direct GP inhibition in vivo rather than inhibition of GP activation by phosphorylase kinase. These results suggest that the cyclin-dependent kinase inhibitor flavopiridol interferes with glycogen degradation, which may be responsible for flavopiridol's cytotoxicity and explain its resistance in some cell lines.",
keywords = "A549, Cancer, Flavopiridol, Glycogen phosphorylase",
author = "Astrid Kaiser and Kayoko Nishi and Gorin, {Fredric A} and Walsh, {Donal A.} and {Morton Bradbury}, E. and Schnier, {Joachim B.}",
year = "2001",
month = "2",
day = "15",
doi = "10.1006/abbi.2000.2220",
language = "English (US)",
volume = "386",
pages = "179--187",
journal = "Archives of Biochemistry and Biophysics",
issn = "0003-9861",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase

AU - Kaiser, Astrid

AU - Nishi, Kayoko

AU - Gorin, Fredric A

AU - Walsh, Donal A.

AU - Morton Bradbury, E.

AU - Schnier, Joachim B.

PY - 2001/2/15

Y1 - 2001/2/15

N2 - Flavopiridol has been shown to induce cell cycle arrest and apoptosis in various tumor cells in vitro and in vivo. Using immobilized flavopiridol, we identified glycogen phosphorylases (GP) from liver and brain as flavopiridol binding proteins from HeLa cell extract. Purified rabbit muscle GP also bound to the flavopiridol affinity column. GP is the rate-limiting enzyme in intracellular glycogen breakdown. Flavopiridol significantly inhibited the AMP-activated GP-b form of the purified rabbit muscle isoenzyme (IC 50 of 1 μM at 0.8 mM AMP), but was less inhibitory to the active phosphorylated form of GP, GP-a (IC 50 of 2.5 μM). The AMP-bound GP-a form was poorly inhibited by flavopiridol (40% at 10 μM). Increasing concentrations of the allosteric effector AMP resulted in a linear decrease in the GP-inhibitory activity of flavopiridol suggesting interference between flavopiridol and AMP. In contrast the GP inhibitor caffeine had no effect on the relative GP inhibition by flavopiridol, suggesting an additive effect of caffeine. Flavopiridol also inhibited the phosphorylase kinase-catalyzed phosphorylation of GP-b by inhibiting the kinase in vitro. Flavopiridol thus is able to interfere with both activating modifications of GP-b, AMP activation and phosphorylation. In A549 NSCLC cells flavopiridol treatment caused glycogen accumulation despite of an increase in GP activity, suggesting direct GP inhibition in vivo rather than inhibition of GP activation by phosphorylase kinase. These results suggest that the cyclin-dependent kinase inhibitor flavopiridol interferes with glycogen degradation, which may be responsible for flavopiridol's cytotoxicity and explain its resistance in some cell lines.

AB - Flavopiridol has been shown to induce cell cycle arrest and apoptosis in various tumor cells in vitro and in vivo. Using immobilized flavopiridol, we identified glycogen phosphorylases (GP) from liver and brain as flavopiridol binding proteins from HeLa cell extract. Purified rabbit muscle GP also bound to the flavopiridol affinity column. GP is the rate-limiting enzyme in intracellular glycogen breakdown. Flavopiridol significantly inhibited the AMP-activated GP-b form of the purified rabbit muscle isoenzyme (IC 50 of 1 μM at 0.8 mM AMP), but was less inhibitory to the active phosphorylated form of GP, GP-a (IC 50 of 2.5 μM). The AMP-bound GP-a form was poorly inhibited by flavopiridol (40% at 10 μM). Increasing concentrations of the allosteric effector AMP resulted in a linear decrease in the GP-inhibitory activity of flavopiridol suggesting interference between flavopiridol and AMP. In contrast the GP inhibitor caffeine had no effect on the relative GP inhibition by flavopiridol, suggesting an additive effect of caffeine. Flavopiridol also inhibited the phosphorylase kinase-catalyzed phosphorylation of GP-b by inhibiting the kinase in vitro. Flavopiridol thus is able to interfere with both activating modifications of GP-b, AMP activation and phosphorylation. In A549 NSCLC cells flavopiridol treatment caused glycogen accumulation despite of an increase in GP activity, suggesting direct GP inhibition in vivo rather than inhibition of GP activation by phosphorylase kinase. These results suggest that the cyclin-dependent kinase inhibitor flavopiridol interferes with glycogen degradation, which may be responsible for flavopiridol's cytotoxicity and explain its resistance in some cell lines.

KW - A549

KW - Cancer

KW - Flavopiridol

KW - Glycogen phosphorylase

UR - http://www.scopus.com/inward/record.url?scp=0035864375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035864375&partnerID=8YFLogxK

U2 - 10.1006/abbi.2000.2220

DO - 10.1006/abbi.2000.2220

M3 - Article

VL - 386

SP - 179

EP - 187

JO - Archives of Biochemistry and Biophysics

JF - Archives of Biochemistry and Biophysics

SN - 0003-9861

IS - 2

ER -